Frozen Shoulder (Adhesive Capsulitis): Causes, Symptoms, Treatment & Prevention

Frozen shoulder, formally adhesive capsulitis, is an inflammatory and fibrotic process of the glenohumeral joint capsule. Histology shows fibroblast and myofibroblast proliferation with type III collagen deposition, particularly in the rotator interval and the coracohumeral and inferior glenohumeral ligaments. The capsule loses compliance, the joint volume contracts and a chronic chemokine-driven cytokine signature drives both pain in the early phase and stiffness in later phases. The disease shares biological features with palmar fibromatosis and is recognised as part of a wider fibroproliferative spectrum in patients with metabolic risk factors.

Clinically, the picture is a stiff, painful shoulder that did not start with a single inciting tear and that worsens slowly over weeks to months. People often describe a very ordinary trigger—reaching for a seatbelt, lifting groceries—followed by escalating night pain and progressive trouble dressing, washing the opposite axilla or reaching the back pocket. Because the capsule sits beneath the rotator cuff, examination shows that both active and passive movement are limited, especially external rotation; that pattern is the single most reliable bedside discriminator and the reason the condition does not respond like a tendon problem to selective rotator cuff strengthening.

The classical Reeves description recognises three overlapping phases. Patients rarely arrive announcing which one they are in—mapping the dominant feature (pain versus stiffness) at every visit lets the team match treatment to the present biology rather than to an imagined timeline.

↔On a small screen, swipe or scroll sideways to see the full table.

Practice note: phase boundaries are conceptual—clinical management should be triggered by what dominates today (pain versus loss of motion versus failure to progress) rather than by a hard month count.

The hallmark complaint is an insidious shoulder pain that becomes worse at night, then morphs into stiffness limiting everyday tasks: reaching overhead, behind the back, or across the body. Patients commonly describe sharp catches at end-range and a deep ache while sleeping on the affected side. The dominant complaint shifts as the disease moves through phases—from pain in the freezing phase to pure stiffness in the frozen phase—but global motion loss is the consistent thread.

Typical features

• Insidious-onset deep joint pain and arm pain referred to the deltoid insertion, often without a discrete injury.
• Night pain that disrupts sleep and prevents lying on the affected side.
• Global, symmetrical joint stiffness with active motion equal to passive motion, both reduced.
• Disproportionate loss of external rotation with the elbow at the side—often the earliest and most striking deficit.
• Functional milestones lost in a recognisable order: hand behind back, doing a bra clasp, hair washing, then overhead reach.

Atypical or under-recognised presentations

• Bilateral disease (sometimes asynchronous) in long-standing diabetes, raising the importance of bilateral assessment from the start.
• Predominant scapular dyskinesis with muscle pain over the trapezius—compensation for capsular restriction rather than primary scapular pathology.
• Stiffness without a markedly painful phase in patients with neuropathy or recent stroke—pain may be blunted while the contracture is brisk.
• Post-procedural cases (after breast surgery, cardiac catheterisation, prolonged sling immobilisation) where the temporal pattern is overlooked because the index event distracts the team.

Frozen shoulder is traditionally split into primary (idiopathic)—where no obvious antecedent is found—and secondary, where a clear systemic, traumatic or post-procedural driver exists. The clinical reasoning is similar; the value of the split is that secondary cases earn a more thorough comorbidity review and an earlier discussion about contralateral risk.

Strong systemic associations

• Diabetes mellitus (type 1 and type 2)—the most consistent association; prevalence rises with disease duration and poor glycaemic control. Bilateral and recurrent disease cluster in this group.
• Thyroid disease—both hypothyroidism and hyperthyroidism are over-represented in case series.
• Hyperlipidaemia and metabolic syndrome appear in registry-style data, plausibly via shared connective-tissue biology.
• Cardiovascular events and post-cardiac surgery (the older “shoulder–hand syndrome” spectrum), including post-myocardial infarction states with prolonged immobilisation.
• Neurological disease—stroke, Parkinson disease and other movement disorders—where reduced active use and tone abnormalities accelerate capsular contracture.
• Breast cancer survivorship—axillary surgery, lymphoedema, radiotherapy and aromatase-inhibitor therapy converge on stiffness in the affected limb.

Local and post-procedural triggers

• Recent shoulder fracture, dislocation or surgical fixation with prolonged sling use.
• Previous rotator cuff repair, calcific tendinopathy episodes or biceps long-head pathology that disrupted normal capsular mechanics.
• Prolonged immobilisation for any reason—including sling use after distal upper-limb fracture or burns rehabilitation.
• Trauma without fracture, including soft-tissue injuries that triggered self-imposed disuse.

Demographics and lifestyle

• Female sex aged 40–60 carries the highest baseline risk in unselected populations.
• Family history of palmar fibromatosis (Dupuytren disease) sits in the same fibroproliferative spectrum and signals systemic susceptibility.
• Sedentary occupational and rehabilitation patterns following trauma further compound risk.

Diagnosis is clinical. There is no single confirmatory test; the role of investigations is to rule out the alternatives that would change management.

Bedside assessment

• Structured history mapping pain quality, night impact, functional milestones lost, comorbidity (diabetes, thyroid, cardiac, oncology, neurology) and prior shoulder events.
• Systematic upper extremity assessment with side-to-side comparison; document active and passive ranges in degrees, including external rotation with the elbow at the side, abduction, flexion and internal rotation behind the back (vertebral level reached).
• Resisted strength testing to screen for rotator cuff pathology (empty can, lift-off, Hornblower, external rotation lag); these are typically intact in pure adhesive capsulitis.
• Targeted neurovascular screen of the limb: pulses, capillary refill, sensation in C5–T1 dermatomes, hand intrinsics, and Spurling test for cervical irritability.
• Validated pain assessment and a baseline functional score (e.g. Oxford Shoulder Score, DASH or Constant–Murley) for shared decision-making and progress tracking.

Imaging

• Plain radiographs (true AP, axillary, scapular Y) are the screening images to exclude glenohumeral osteoarthritis, calcific tendinopathy, dislocation, fracture sequelae, and avascular necrosis of the humeral head.
• Ultrasound can document coracohumeral ligament thickening (≥3–4 mm in some series), loss of normal axillary recess gliding and secondary signs while excluding full-thickness cuff tears.
• Magnetic resonance imaging with or without arthrography is reserved for diagnostic uncertainty—classical findings include capsular and coracohumeral ligament thickening, axillary recess thickening with contrast enhancement, and rotator interval oedema.

Targeted laboratory work

• HbA1c when diabetes has not been screened recently or control is suboptimal.
• Thyroid-stimulating hormone when thyroid disease is suspected by history or examination.
• CRP and ESR only when an alternative—septic arthritis, polymyalgia rheumatica or inflammatory arthropathy—is on the differential list.
• Nerve conduction studies in selected cases when concomitant carpal tunnel syndrome or cervical radiculopathy clouds the picture.

Diagnostic anchor

The clinching combination is: insidious onset of shoulder pain with global, symmetrical loss of active and passive range (especially external rotation), preserved rotator cuff strength, and a plain radiograph that does not show another structural cause. Where any of those four anchors fails, escalate the workup rather than escalating treatment intensity.

Most management mistakes in stiff shoulders come from the wrong label. The grid below pairs the alternative with the bedside or imaging discriminator that most reliably moves the diagnosis.

↔On a small screen, swipe or scroll sideways to see the full table.

Treatment is layered: clear education on the natural course, simple analgesia, supervised physiotherapy paced to phase, well-timed intra-articular corticosteroid in the painful phase, and a small number of procedural options reserved for refractory disease. Doses below are illustrative; dispense per local formulary and prescriber direction.

First-line management

• Education on natural history. Explaining the freezing–frozen–thawing arc up front improves engagement, reduces low-value imaging requests and prepares patients for a months-long timeline.
• Simple analgesia. Acetaminophen as the analgesic backbone; oral NSAIDs—ibuprofen or naproxen—for short courses when gastrointestinal, renal and cardiovascular risks are checked. Topical diclofenac is reasonable for some patients with absolute contraindications to oral NSAIDs.
• Supervised physiotherapy matched to phase: pain-respecting passive and active-assisted mobility in the freezing phase, structured stretching and scapular control in the frozen phase, and progressive strengthening in the thawing phase. Range of motion exercises and home self-mobilisation routines reinforce gains made in clinic.
• Comfort adjuncts: heat application before exercise sessions improves stretch tolerance for many patients; sleep positioning with a pillow under the affected arm reduces night flares.

Image-guided and injectable options

• Intra-articular corticosteroid injection—commonly triamcinolone or methylprednisolone with local anaesthetic—delivers the clearest short-to-medium-term pain and function benefit when given in the painful (freezing) phase combined with physiotherapy. Repeat injections without measurable progress add little.
• Hydrodilatation (capsular distension): image-guided injection of a larger volume of saline plus local anaesthetic and corticosteroid to mechanically stretch the contracted capsule. Pragmatic randomised data (notably the UK FROST trial) suggest broadly similar function outcomes to early structured physiotherapy or manipulation under anaesthesia, with cost and access shaping the choice locally.
• Suprascapular nerve block: useful adjunct for analgesia in the painful phase when intra-articular steroid is contraindicated or being supplemented.
• Short oral corticosteroid courses—e.g. tapering prednisone—can offer brief pain relief but are not a routine first-line strategy and demand a clear glycaemic and bone-health discussion in at-risk patients.

Surgical and procedural escalation

• Manipulation under anaesthesia (MUA): controlled passive motion under general or regional anaesthesia to disrupt capsular contracture; effective for selected patients but requires careful screening for osteoporosis and a structured rehabilitation plan to consolidate gains.
• Arthroscopic capsular release: targeted division of the rotator interval and contracted capsule under direct vision; commonly chosen for refractory disease, especially in people with diabetes who plateau early.
• Open capsular release: reserved for revision contexts or when concomitant pathology is being addressed.

Special populations

• Diabetes: warn patients about transient hyperglycaemia for several days after intra-articular or systemic steroid; coordinate blood glucose monitoring and review hypoglycaemic agents before injection. Lower threshold for early surgical referral when conservative care plateaus.
• Cardiovascular comorbidity: NSAID risks rise with antiplatelet, anticoagulant or heart-failure regimens—prefer paracetamol and physiotherapy-led plans, with cautious short NSAID courses when essential.
• Pregnancy and lactation: avoid systemic NSAIDs (especially in the third trimester) and most systemic steroids unless pregnancy-specialist input is documented; physiotherapy and topical analgesia carry the management.
• Older adults and post-stroke patients: screen for osteoporosis before MUA, plan falls precautions during home exercises, and integrate with broader rehabilitation goals.
• Breast cancer survivors: coordinate with oncology and lymphoedema services; avoid blood pressure and venepuncture on the affected side per local survivorship pathways.

Operationalise the same loop at every visit: confirm phase, score pain and function, check adherence, screen for systemic drivers and reset the escalation clock.

Monitoring cadence

• Review at 4–6 weeks after starting structured physiotherapy and at 6–12 weeks after intra-articular steroid—earlier if pain is worsening or new red flags appear.
• Document degrees of motion, validated pain score and a functional measure each visit; trends matter more than absolute numbers in a slow disease.
• Check blood glucose around steroid procedures in people with diabetes; reinforce medication reconciliation when adding NSAIDs or oral steroids to chronic regimens.

Treatment-failure flags

• No measurable functional progress at 12 weeks despite supervised physiotherapy and at least one image- or landmark-guided intra-articular intervention.
• Escalating night pain, new neurological signs or constitutional symptoms—escalate diagnostically rather than therapeutically.
• Inability to perform vocational tasks (driving, occupational reach demands) for more than three months despite engagement with rehabilitation.

Decision flow (shift-ready)

1. Confirm pattern: insidious onset, global active and passive restriction, preserved cuff strength, normal radiograph → likely adhesive capsulitis.
2. Identify phase: pain-dominant (freezing) → analgesia + intra-articular steroid + physiotherapy; stiffness-dominant (frozen) → graded stretching + consider hydrodilatation or nerve block; recovering (thawing) → progressive strengthening, return-to-activity goals.
3. Screen drivers: HbA1c, TSH, comorbidity audit; counsel on contralateral risk in diabetic patients.
4. Reassess at 6–12 weeks; if no progress, escalate to surgical opinion (MUA or arthroscopic release) rather than repeating steroid indefinitely.
5. Document goal-linked outcomes (dressing, driving, occupational tasks) so reviewers see objective change, not just narrative.

Bedside monitoring checklist

• Mobility assessment with documented degrees for flexion, abduction, external rotation and internal rotation behind back.
• Sleep diary or simple night-pain score across visits.
• Capillary glucose around steroid days for patients with diabetes; falls risk on days when range or analgesia changes substantially.
• Skin and shoulder-girdle observation for post-immobilisation deconditioning, scapular dyskinesis or asymmetric muscle bulk.

• Persistent stiffness or measurable functional deficit—reported in roughly 6–50% of patients depending on cohort, severity and presence of diabetes.
• Contralateral involvement, often asynchronous, in about 6–17% of cases; counsel diabetic patients explicitly.
• Sleep deprivation, low mood and reduced occupational capacity—screen and refer; chronic pain overlaps with depression and anxiety disorders.
• Steroid-related adverse effects: transient hyperglycaemia, rare septic arthritis after injection, cutaneous atrophy at injection site, facial flushing.
• Manipulation-related complications: humeral fracture, dislocation, rotator cuff or labral injury—mitigated by careful patient selection and bone-health screening.
• Post-surgical stiffness recurrence or incomplete release, especially when post-procedural rehabilitation is interrupted.
• Iatrogenic deconditioning when sling immobilisation is over-prescribed for “rest”—a powerful preventable driver of secondary capsulitis after upper-limb injuries.

Clinician-facing prevention focuses on the levers that actually move outcomes: minimise duration of post-injury or post-surgical immobilisation, prescribe early shoulder mobility programmes after stroke and after breast or cardiac surgery, address glycaemic control and metabolic risk in people with diabetes, and educate at-risk groups (diabetes, thyroid disease, breast cancer survivors) to flag early stiffness rather than wait for severe night pain. Vaccination, fall prevention and bone-health optimisation matter for the broader rehabilitation plan, especially before any planned manipulation.

Most patients with idiopathic adhesive capsulitis improve substantially within 12–30 months, although that timeline frequently surprises people who arrived expecting weeks rather than months. A meaningful minority retain measurable stiffness on examination even when symptoms are mild, particularly in long-standing or poorly controlled diabetes. Recurrence in the same shoulder is uncommon; contralateral involvement is the more realistic risk to discuss. Realistic counselling—control of pain, progressive return of function, slow trajectory—usually beats over-promising a rapid cure and protects engagement with rehabilitation.

Reframing rest

Patients arrive expecting that immobilising the shoulder will let it heal; the opposite is usually true. Coach progressive movement within tolerable pain, demonstrate self-mobilisation drills and turn home exercise into a daily ritual rather than a chore.

Sleep and analgesia

Night pain is often what drives presentation. Practical sleep coaching—pillow under the affected arm, semi-reclined positions, simple analgesia an hour before bed when prescribed—makes the difference between a patient who can engage with physiotherapy and one who cannot.

Workforce realism

Capture vocational demands in plain language: lifting weights, overhead tasks, driving distances, typing posture. Concrete documentation supports occupational health conversations and helps the team time procedural escalation against work goals.

Equity and literacy

Translate “adhesive capsulitis” into useable language; avoid pain-catastrophising scripts and ensure non-English-speaking patients receive interpreted explanations of the freezing–frozen–thawing arc. Steroid-phobic patients respond to honest framing about transient blood-glucose effects rather than dismissive reassurance.

Escalation triggers

• New neurological signs in the limb—sensory loss, motor weakness, hand wasting.
• Constitutional symptoms or rest pain unrelieved by position—reconsider malignancy, infection or AVN.
• Acute trauma during exercise with sudden weakness—exclude superimposed rotator cuff or proximal humerus injury.
• Glycaemic decompensation after intra-articular or systemic steroid—coordinate with diabetes team early.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and a compact cloze on the topic of frozen shoulder (adhesive capsulitis) recognition (freezing / frozen / thawing phases), structured stepped pain / physiotherapy / intra-articular steroid / hydrodilatation / capsular-release ladder and the missed-fracture / septic-arthritis / referred-ischaemia red flags.